Chugai Pharmaceutical Establishes U.S. Partnering Office to Accelerate Global Open Innovation Strategy
Key Insights
Chugai Pharmaceutical announced the establishment of a new partnering office in South San Francisco, set to begin operations in January 2026 under the leadership of Andrew Wong.
The office will strengthen Chugai's network with U.S. academia and startups while advancing strategic external partnership activities as part of the company's goal to become a top global healthcare innovator by 2030.
This expansion complements Chugai's existing global partnering network, including operations in Japan, the UK, and Singapore, along with the Chugai Venture Fund (search) in Boston.
Chugai Pharmaceutical Co., Ltd. announced the establishment of a new partnering office in South San Francisco, marking a significant expansion of the Japanese pharmaceutical company's global open innovation strategy. The Chugai Partnering US Office will begin operations in January 2026 as a branch of the company's wholly-owned subsidiary, Chugai Pharma USA (search), Inc.
Strategic Leadership and Vision
The new office will be headed by Andrew Wong, who brings extensive experience from key business development positions at leading global pharmaceutical companies and research institutions. According to Dr. Osamu Okuda, Chugai's President and CEO, the office represents a crucial step in the company's ambitious goal to become a top innovator in the global healthcare industry by 2030.
"By further strengthening our network with local academia and start-ups, we will advance our search for technologies from external organizations and target identification technologies that have synergies with Chugai's drug discovery technologies," Dr. Okuda stated.
Comprehensive Global Network
The South San Francisco office will integrate with Chugai's existing global partnering infrastructure, which includes the company's head office in Japan and wholly-owned subsidiaries Chugai Pharma Europe Ltd. in the UK and Chugai Pharmabody Research Pte. Ltd. (search) in Singapore. These entities have been actively advancing partnerships with local companies and research institutions in their respective regions.
The establishment of the U.S. office creates a comprehensive framework for worldwide partnership activities, enabling Chugai to collaborate with its partnering functions across multiple regions to accelerate global open innovation initiatives.
Strategic Focus Areas
Located at 601 Gateway Blvd in South San Francisco, the office will focus on three primary objectives: exploring partnerships with academia and startups in the U.S., collecting information on the U.S. ecosystem while building networks with academia, venture capitals, and startups, and enhancing Chugai's brand recognition globally.
The office will work in conjunction with Chugai's existing investment activities through the Chugai Venture Fund (search) based in Boston, which focuses on external startups and cutting-edge technologies. This dual approach of direct partnerships and venture investments positions Chugai to access a broader spectrum of innovation opportunities in the U.S. market.
Open Innovation as Growth Driver
Chugai has positioned open innovation as one of the key drivers to achieve its 2030 strategic goals. The company's approach emphasizes identifying external technologies and target identification capabilities that complement its internal drug discovery platforms, creating synergistic opportunities for therapeutic development.
The expansion into the U.S. market through this dedicated partnering office reflects the pharmaceutical industry's increasing recognition of the importance of external collaboration in driving innovation and maintaining competitive advantage in drug development.